September 24, 2025

Peptide–oligonucleotide conjugates (POCs) are innovative hybrid molecules that combine the targeting precision of peptides with the gene-modulating power of oligonucleotides. Linking these components greatly improves stability, supports efficient cellular uptake, and enables more precise therapeutic delivery.

The treatment landscape for genetic and rare diseases is being reshaped by exciting advances in oligonucleotide therapeutics, such as antisense oligos (ASOs), small interfering RNA (siRNA), and aptamers. However, delivery and stability continue to pose significant hurdles.

POCs address these barriers in several ways:

Despite their therapeutic potential, peptide–oligo conjugates must also contend with unique technical complexities:

• Chemistry – designing stable conjugation strategies that preserve both peptide and oligo activity
• Manufacturing – scaling up requires tightly integrated peptide and oligonucleotide synthesis at GMP quality
• Analytics – hybrid molecules demand advanced methods for purity, stability, and potency testing
• Regulatory pathways – as cross-modal products, POCs require expertise in both peptide and oligo CMC frameworks

CPC Scientific is uniquely positioned to accelerate POC development with fully in-house peptide, oligonucleotide, and peptide–oligo conjugate capabilities, all under one roof. This integrated platform streamlines development and reduces outsourcing risks, while ensuring both quality and speed from discovery through commercial supply.

Our team is backed by nearly 25 years of peptide manufacturing expertise across GMP and non-GMP SPPS, with capabilities spanning early discovery and scaling into the tons. Our state-of-the-art oligonucleotide facilities cover synthesis, purification, and analytical technologies. By combining these resources with our proprietary conjugation chemistries, we’re able to deliver a seamlessly end-to-end peptide–oligonucleotide conjugate platform with full integration and control across the POC value chain.

Our dedicated POC services include a wide range of chemical modifications, such as:

Using a parallel synthetic approach, CPC Scientific supports a broad range of conjugation strategies including amide bonds, disulfide bridges, thioether linkages, and triazole click chemistry. This flexibility allows us to easily tailor POCs for optimal performance across diverse functions and contexts, balancing stability and delivery with therapeutic efficiency.

With these factors optimized, conjugates can help drive breakthroughs in critical areas such as neurodegenerative diseases, ophthalmology, oncology, respiratory diseases, and viral infections. In each of these areas, therapeutic success often hinges upon overcoming barriers to delivery, uptake, and intracellular distribution — precisely the same challenges POCs are designed to solve.

Explore the white papers and brochures below to learn more about our approach to peptide–oligonucleotide conjugation:

Peptide–oligonucleotide conjugates present a new frontier in therapeutic design, combining the strengths of both peptides and oligonucleotides into a single modality with tremendous potential. But harnessing this potential requires technical integration and a nuanced understanding of regulatory requirements in order to navigate the complex manufacturing challenges presented.

As a global peptide and oligo CDMO, CPC Scientific brings together these key capabilities, so that we can deliver true end-to-end support for your therapeutic platforms. Our integrated in-house POC services, deep technical expertise, world-class facilities, and proven regulatory track record make us a trusted partner for translating POCs into real-world therapies, from concept to commercial.

Ready to advance your next-generation peptide–oligo conjugate therapeutics? Request a quote or reach out to oligo@cpcscientific.com to explore how our team can move your programs forward.